News - Desert King

Desert King® and the Vaccine Formulation Institute: A Strategic Alliance for Global Access to Vaccine Adjuvants

Desert King® (DK) and the Vaccine Formulation Institute (VFI) have joined forces in a strategic alliance to revolutionize global access to vaccine adjuvants.

Desert King® achieves EXCiPACT™ certification and strengthens its leadership in vaccine adjuvant production

Desert King®, a global leader in the vaccine adjuvant market based on Quillaja saponaria saponins, is proud to announce his EXCiPACT™ certification.

Ye, L., et al. Effects of immune response on different nano-adjuvants combined with H11 antigen of Haemonchus contortus.

The study indicates that nano-adjuvants offer a promising alternative to traditional adjuvants for inducing robust and lasting immune responses, particularly in the conte...

Ma W. et. al.: Enhanced Antitumor Immunity of a Globo H-Based Vaccine Enabled by the Combination Adjuvants of 3D-MPL and QS-21.

The study presents a novel adjuvant-assisted Globo H-based anticancer vaccine platform. The article advocates for the efficacy of a combination QS-21/3D-MPL adjuvant.

Venkatraman, N., et al. Evaluation of a novel malaria anti-sporozoite vaccine candidate, R21 in Matrix-M adjuvant, in the UK and Burkina Faso: two phase 1, first-in-human trials.

Comments from Desert King: The R21/Matrix-M malaria vaccine uses Novavax's proprietary Matrix-M adjuvant technology to help prevent malaria in children. The R21 Ag was de...

Pirahmadi S. et. al.: Selection of combination adjuvants for enhanced immunogenicity of a recombinant CelTOS vaccine against Plasmodium falciparum.

In the current study, the immunogenicity of Plasmodium falciparum cell traversal protein for ookinetes and sporozoites (PfCelTOS) were intended to improve by three differ...

Luna, E., et al. SPA14 liposomes combining saponin with fully synthetic TLR4 agonist provide adjuvanticity to hCMV vaccine candidate.

An innovative novel adjuvant system, SPA14, which combines the QS-21 saponin with a synthetic TLR4 agonist, E6020, in cholesterol-containing liposomes, has shown promisin...

Yousefpour, P., et al. Modulation of antigen delivery and lymph node activation in nonhuman primates by saponin adjuvant saponin/monophosphoryl lipid A nanoparticle.

This article emphasizes the significance of the saponin QS-21/monophosphoryl lipid A nanoparticles (SMNP) using an HIV Env trimer model Ag, in enhancing immune responses ...